Merrimack Pharmaceuticals (MACK)
(Delayed Data from NSDQ)
$14.73 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.71 -0.02 (-0.14%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MACK 14.73 0.00(0.00%)
Will MACK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MACK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MACK
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
MACK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MACK
Merrimack Receives $225 Million Milestone Payment from Ipsen
Merrimack’s FDA Approval Milestone and Scheduled Dissolution Vote
Merrimack receives $225M milestone payment from Ipsen
Merrimack receives $225M milestone payment from Ipsen
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023